Pulmonx Corporation shows deteriorating financial position with market value declining significantly from $239.4M to $101.4M while maintaining modest revenue growth.
The company's market capitalization fell substantially over the year, reflecting investor concerns despite achieving revenue growth from $83.8M to $90.5M. The improved net loss position (from $56.4M to $54.0M) and stable gross margins around 74% suggest operational execution remains on track, though the dramatic market value decline indicates broader investor skepticism about the company's prospects or market conditions.
The balance sheet shows meaningful contraction with stockholders' equity declining 37% to $54.1M and total assets falling 21% to $129.3M, suggesting cash burn continues. Current liabilities decreased modestly by 18%, while R&D expenses grew 11% to $19.5M, indicating continued investment in product development. Capital expenditures dropped substantially to $452K, potentially signaling reduced infrastructure investment or completion of prior expansion plans.
Capex reduced 68.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 25.4% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 20.6% — asset sales, write-downs, or balance sheet optimization underway.
Current liabilities reduced — improved short-term financial position and working capital health.
R&D investment increased 10.9% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →